Solubility
50 μM in 0.1% (v/v) DMSO / aqueous buffers.
Pre-dissolve e.g. 10 mg (5.39 μmol) in 108 μl DMSO - dilute e.g. 10 μl of that stock solution (50 mM) with 9990 μl aqueous buffer to obtain a 50 μM solution. DMSO stock solutions are sterile and can be stored at -20°C for at least 6 months. To avoid too many freeze-thaw cycles, we strongly recommend storage of aliquots.
Reference(s)
Oertel, K. et al. Anal. Biochem. 2007, 367, 152.
Dodt, J. et al. Anal. Biochem. 2013, 439, 145.
Berny‐Lang, M.A. et al. J. Am. Heart Assoc. 2013, 2, e000026.
Schroeder, V. et al. Br. J. Haematol. 2015, 168, 757.
de Jager, M. et al. Neuropathol. Appl. Neurobiol. 2016, 42, 255.
Király, R. et al. Amino Acids 2016, 48, 31.
van der Wildt, B. et al. Nucl. Med. Biol. 2016, 43, 232.
Dodt, J. et al. Br. J. Haematol. 2016, 172, 452.
Chrobok, N.L. et al. PLoS ONE 2018, 13, e0209522.
Akbar, A. et al. J. Med. Chem. 2017, 60, 7910-7927.
Singh, S. et al. Int. J. Mol. Sci. 2019, 20, 2682.
Gates et al., Molecules 2023, 28:1634.
Note
The molecular weight was corrected to 1853.95, taking into account that A101 traps only one TFA counter ion instead of two counter ions as stated in PDS RN3.1 from 07 May 2014. The presence of one TFA counter ion is valid for all former batches, too.
Background: During the course of our continuous quality assurance process, Zedira developed a novel method to quantify the TFA counter ion content by using a 19F NMR method according to Little et al. (J. Pharm. Biomed. Anal. 2007, 43, 1324), based on an internal standard.
Please note that neither the synthesis and purification nor the product as such has been changed. Please consider the molecular weight correction if necessary.
Intended for research use only, not for use in human, therapeutic or diagnostic applications.